Heart surgery showdown: which fix best unblocks the heart?
NCT ID NCT03877731
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 100 people with hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Researchers compared different surgical techniques—removing part of the thickened heart muscle alone or combined with repairing the mitral valve—to see which best relieves symptoms and keeps patients out of the hospital. The goal is to find the most effective surgery for this heart problem.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- surgery (septal myectomy with or without mitral valve repair)
- What this could lead to
- If successful, this could identify the best surgical approach to relieve heart blockage and improve survival without hospital readmission for people with hypertrophic cardiomyopathy.
- What could go wrong
- This is a completed observational study with 100 participants, not a large randomized trial. Results may not apply to all patients, and surgery carries risks like infection or heart complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Dec 2006
- Finished
-
Sep 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>18 years * Signed informed consent to participate in the study * For patients with hypertrophic cardiomyopathy only: resting or latent peak left ventricular outflow tract gradient \>50 mmHg, NYHA class III-IV * For patients with arterial hypertension only: hystory of arterial pressure increase \>140/90 mmHg, increased left vantricular wall thickness (\>10 mm) and myocardial mass indexed to BSA (\>95 g/m2 for women and \>115 g/m2 for men), as assessed by 2D transthoracic echocardiography Exclusion Criteria: * Age \< 18 years * Persistent form of atrial fibrillation * Intrinsic mitral or aortic valve disease * Coronary artery disease * Reduced left ventricular ejection fraction * For control group only: presence of any structural heart disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Arterial hypertension with left ventricular hypertrophy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cardiology research institute, National Research Medical Center of the Russian Academy of Sciences
Tomsk, 634012, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.